The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
Open accessPublished version of a preprint
Abstract
Immune-checkpoint inhibitors and adoptive tumor-infiltrating lymphocyte (TIL) therapies have profoundly improved the survival of patients with melanoma. However, a majority of patients do not respond to these agents, and many responders experience disease relapse. Although numerous innovative treatments are being explored to offset the limitations of these agents, novel therapeutic combinations with immunotherapies have the potential to improve patient responses. In this study, we evaluated the antimelanoma activity of immunotherapy combinations with Telaglenastat (CB-839), a potent glutaminase inhibitor (GLSi) that has favorable systemic tolerance. In in vitro TIL:tumor coculture studies, CB-839 treatment improved the cytotoxic activity of autologous TILs on patient-derived melanoma cells. CB-839 treatment decreased the conversion of glutamine to alpha-ketoglutarate (αKGA) more potently in tumor cells versus TILs in these cocultures. These results suggest that CB-839 may improve immune function in a tumor microenvironment by differentially altering tumor and immune cell metabolism. In vivo CB-839 treatment activated melanoma antigen–specific T cells and improved their tumor killing activity in an immune-competent mouse model of adoptive T-cell therapy. Additionally, the combination of CB-839 with anti-PD1 or anti-CTLA4 antibodies increased tumor infiltration by effector T cells and improved the antitumor activity of these checkpoint inhibitors in a high mutation burden mouse melanoma model. Responsiveness to these treatments was also accompanied by an increase of interferon gamma (IFNγ)–associated gene expression in the tumors. Together, these results provide a strong rationale for combining CB-839 with immune therapies to improve efficacy of these treatments against melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Besides, other metabolic modulators such as glutaminase inhibitor also had a synergistic effect with α-PD-1/PD-L1 in murine tumor models [338].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [338]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Metabolic alterations facilitate cancer cells to obtain nutrients and building blocks needed for their unfettered growth, metastases, and therapeutic resistance (1).”
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731 · cited 1×
“IHC analysis Tumors were harvested at the indicated times, and immunostaining was performed on tissue sections using standard methodology, scanned and analyzed as described earlier (31).”
Self-citationRegulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620 · cited 1×
“As the observed effector TIL status may only be a snapshot of the specific time of measurement, and potentially influenced by factors such as effector cell exhaustion or alterations in myeloid/regulatory T cells (34), longitudinal studies exploring the numbers of effector and regulatory T cells at different time inter…”
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · cited 1×
“We next measured the effect of CB-839 on intracellular glutamine and its GLS-catalyzed products using LC-MS in monocultures of gp100 antigen–specific Pmel-1 T cells; monocultures of A375HG melanoma cells that express murine MHCclass I andgp100, allowing recognitionby thePmel-1T cells (32); or the cocultures of Pmel-1…”
Self-citationGlutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169 · cited 1×
“For example, inhibitors of glutamine uptake like benzylserine and irreversible glutamine analogues such as 6-diazo-5-oxo-L-norleucine (DON) exhibit unacceptable systemic toxicity (12), although a recent prodrug version may be more tolerable (13).”
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068 · cited 4×
“In a clinical study of CB-839 combination with anti-PD1 in patients with melanoma who had earlier progressed with checkpoint inhibitor therapy (15), the expression of a set of genes termed “T-cell– inflamed signature” was predictive of objective responses versus progressive disease.”
InfluentialSelf-citationWang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., Mirsoian, A., Minnar, C. M., Stoffel, K. M., Sturgill, I. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0221-5 · Cited by 865 · cited 1×
“Mice were administered twice-daily treatments of CB-839 as above, or twice-a-week intraperitoneal injections of anti-CTLA4 (100 mg/animal) or anti-PD1 (500 mg/animal) as suggested (20, 30), either as single agents or in combination with each other and with CB-839.”
Carr, E. L., Kelman, A., Wu, G. S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A. M., & Frauwirth, K. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903586 · Cited by 830 · cited 1×
“In addition to being a critical nutrient for cancer cells, glutamine is also important for immune cell function, including T-lymphocyte activation (17, 18).”
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.003 · Cited by 818 · cited 10×
“Mol Cancer Ther; 20(3) March 2021 MOLECULAR CANCER THERAPEUTICS 506”
Influential
Research works printed but not linked: 1
- Meric-Bernstam, 2017, CX-839-004: A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
“Besides, other metabolic modulators such as glutaminase inhibitor also had a synergistic effect with α-PD-1/PD-L1 in murine tumor models [338].”
BackgroundTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 836
Targeting glutamine metabolism as a therapeutic strategy for cancer
Jin, J., Byun, J., Choi, Y., & Park, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00971-9 · Cited by 605
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 484
Cancer cell metabolism and antitumour immunity
Martino, M. D., Rathmell, J. C., Galluzzi, L., & Vanpouille‐Box, C. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 385
“That said, telaglenastat has also been shown to synergize with CTLA4 and PD1 blockers in immunocompetent models of melanoma 126 , which suggests that this agent does mediate therapeutically relevant immunostimulatory effects.”
Metadata
- Authors
- Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., Mackinnon, A. L., McQuade, J. L., Hailemichael, Y., Roszik, J., Peng, W., & Vashisht Gopal, Y. N.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Calithera (United States) (US)
- University of Houston (US)
- 1Department of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX.
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2021-03-01
- Volume
- 20
- Issue
- 3
- Pages
- 500-511
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC7933078
- OpenAlex
- W3116829754
- Cited by
- 171
- References
- 35
- Citations by year
- 2026: 31 · 2025: 50 · 2024: 36 · 2023: 17 · 2022: 26 · 2021: 11
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Melanoma Research Alliance (348483)
- Calithera Biosciences (55350)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CB-839, telaglenastat, glutaminase inhibitors, melanoma, adoptive T cell therapy, tumor-infiltrating lymphocytes, immune checkpoint inhibitors, anti-PD-1, anti-CTLA-4, alpha-ketoglutarate, cancer metabolism, interferon-gamma, tumor microenvironment, combination immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Glutaminase, Humans, Immunotherapy, Melanoma, T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
